nodes	percent_of_prediction	percent_of_DWPC	metapath
Irbesartan—CYP1A2—Riluzole—amyotrophic lateral sclerosis	0.432	1	CbGbCtD
Irbesartan—Cardiac murmur—Riluzole—amyotrophic lateral sclerosis	0.0156	0.0467	CcSEcCtD
Irbesartan—Stiffness—Riluzole—amyotrophic lateral sclerosis	0.0127	0.0381	CcSEcCtD
Irbesartan—JUN—peripheral nervous system—amyotrophic lateral sclerosis	0.0112	0.17	CbGeAlD
Irbesartan—Lymphopenia—Riluzole—amyotrophic lateral sclerosis	0.00942	0.0283	CcSEcCtD
Irbesartan—JUN—nerve—amyotrophic lateral sclerosis	0.0087	0.132	CbGeAlD
Irbesartan—Myasthenia—Riluzole—amyotrophic lateral sclerosis	0.00767	0.0231	CcSEcCtD
Irbesartan—Respiratory distress—Riluzole—amyotrophic lateral sclerosis	0.00759	0.0228	CcSEcCtD
Irbesartan—Blood creatine phosphokinase increased—Riluzole—amyotrophic lateral sclerosis	0.00701	0.0211	CcSEcCtD
Irbesartan—JUN—hindbrain—amyotrophic lateral sclerosis	0.00651	0.0991	CbGeAlD
Irbesartan—Glycosuria—Riluzole—amyotrophic lateral sclerosis	0.00595	0.0179	CcSEcCtD
Irbesartan—Musculoskeletal stiffness—Riluzole—amyotrophic lateral sclerosis	0.00537	0.0162	CcSEcCtD
Irbesartan—Gout—Riluzole—amyotrophic lateral sclerosis	0.00516	0.0155	CcSEcCtD
Irbesartan—Coordination abnormal—Riluzole—amyotrophic lateral sclerosis	0.00491	0.0148	CcSEcCtD
Irbesartan—Aplastic anaemia—Riluzole—amyotrophic lateral sclerosis	0.00453	0.0136	CcSEcCtD
Irbesartan—Ecchymosis—Riluzole—amyotrophic lateral sclerosis	0.00436	0.0131	CcSEcCtD
Irbesartan—Pulmonary oedema—Riluzole—amyotrophic lateral sclerosis	0.00429	0.0129	CcSEcCtD
Irbesartan—Ear pain—Riluzole—amyotrophic lateral sclerosis	0.0041	0.0123	CcSEcCtD
Irbesartan—JUN—embryo—amyotrophic lateral sclerosis	0.00407	0.062	CbGeAlD
Irbesartan—Diabetes mellitus—Riluzole—amyotrophic lateral sclerosis	0.00402	0.0121	CcSEcCtD
Irbesartan—Hepatic function abnormal—Riluzole—amyotrophic lateral sclerosis	0.004	0.012	CcSEcCtD
Irbesartan—Photosensitivity—Riluzole—amyotrophic lateral sclerosis	0.00399	0.012	CcSEcCtD
Irbesartan—Injury—Riluzole—amyotrophic lateral sclerosis	0.00381	0.0114	CcSEcCtD
Irbesartan—JUN—brainstem—amyotrophic lateral sclerosis	0.00373	0.0568	CbGeAlD
Irbesartan—Increased appetite—Riluzole—amyotrophic lateral sclerosis	0.00373	0.0112	CcSEcCtD
Irbesartan—Arthritis—Riluzole—amyotrophic lateral sclerosis	0.0036	0.0108	CcSEcCtD
Irbesartan—Hyponatraemia—Riluzole—amyotrophic lateral sclerosis	0.00351	0.0106	CcSEcCtD
Irbesartan—Affect lability—Riluzole—amyotrophic lateral sclerosis	0.00345	0.0104	CcSEcCtD
Irbesartan—Face oedema—Riluzole—amyotrophic lateral sclerosis	0.00338	0.0102	CcSEcCtD
Irbesartan—Mood swings—Riluzole—amyotrophic lateral sclerosis	0.00332	0.00996	CcSEcCtD
Irbesartan—Liver function test abnormal—Riluzole—amyotrophic lateral sclerosis	0.00323	0.00971	CcSEcCtD
Irbesartan—Orthostatic hypotension—Riluzole—amyotrophic lateral sclerosis	0.0032	0.00961	CcSEcCtD
Irbesartan—Hypokalaemia—Riluzole—amyotrophic lateral sclerosis	0.00319	0.00957	CcSEcCtD
Irbesartan—Breast disorder—Riluzole—amyotrophic lateral sclerosis	0.00316	0.0095	CcSEcCtD
Irbesartan—Muscular weakness—Riluzole—amyotrophic lateral sclerosis	0.00309	0.00928	CcSEcCtD
Irbesartan—Abdominal distension—Riluzole—amyotrophic lateral sclerosis	0.00305	0.00915	CcSEcCtD
Irbesartan—Dysphagia—Riluzole—amyotrophic lateral sclerosis	0.00303	0.00909	CcSEcCtD
Irbesartan—Influenza—Riluzole—amyotrophic lateral sclerosis	0.00303	0.00909	CcSEcCtD
Irbesartan—Asthma—Riluzole—amyotrophic lateral sclerosis	0.00303	0.00909	CcSEcCtD
Irbesartan—Pancreatitis—Riluzole—amyotrophic lateral sclerosis	0.00297	0.00891	CcSEcCtD
Irbesartan—Angina pectoris—Riluzole—amyotrophic lateral sclerosis	0.00295	0.00885	CcSEcCtD
Irbesartan—EDNRA—medulla oblongata—amyotrophic lateral sclerosis	0.00285	0.0434	CbGeAlD
Irbesartan—Neutropenia—Riluzole—amyotrophic lateral sclerosis	0.00283	0.0085	CcSEcCtD
Irbesartan—Photosensitivity reaction—Riluzole—amyotrophic lateral sclerosis	0.00276	0.0083	CcSEcCtD
Irbesartan—Weight increased—Riluzole—amyotrophic lateral sclerosis	0.00275	0.00827	CcSEcCtD
Irbesartan—Pneumonia—Riluzole—amyotrophic lateral sclerosis	0.00271	0.00815	CcSEcCtD
Irbesartan—Acute coronary syndrome—Riluzole—amyotrophic lateral sclerosis	0.00266	0.00799	CcSEcCtD
Irbesartan—Myocardial infarction—Riluzole—amyotrophic lateral sclerosis	0.00264	0.00794	CcSEcCtD
Irbesartan—Jaundice—Riluzole—amyotrophic lateral sclerosis	0.00263	0.0079	CcSEcCtD
Irbesartan—Urinary tract infection—Riluzole—amyotrophic lateral sclerosis	0.00262	0.00788	CcSEcCtD
Irbesartan—JUN—medulla oblongata—amyotrophic lateral sclerosis	0.0026	0.0396	CbGeAlD
Irbesartan—Hepatobiliary disease—Riluzole—amyotrophic lateral sclerosis	0.00255	0.00767	CcSEcCtD
Irbesartan—Epistaxis—Riluzole—amyotrophic lateral sclerosis	0.00254	0.00764	CcSEcCtD
Irbesartan—Agranulocytosis—Riluzole—amyotrophic lateral sclerosis	0.00252	0.00756	CcSEcCtD
Irbesartan—Bradycardia—Riluzole—amyotrophic lateral sclerosis	0.00247	0.00741	CcSEcCtD
Irbesartan—Rhinitis—Riluzole—amyotrophic lateral sclerosis	0.00243	0.00729	CcSEcCtD
Irbesartan—Hepatitis—Riluzole—amyotrophic lateral sclerosis	0.00242	0.00728	CcSEcCtD
Irbesartan—Hypoaesthesia—Riluzole—amyotrophic lateral sclerosis	0.00241	0.00724	CcSEcCtD
Irbesartan—Pharyngitis—Riluzole—amyotrophic lateral sclerosis	0.0024	0.00722	CcSEcCtD
Irbesartan—Urinary tract disorder—Riluzole—amyotrophic lateral sclerosis	0.00239	0.00719	CcSEcCtD
Irbesartan—Oedema peripheral—Riluzole—amyotrophic lateral sclerosis	0.00239	0.00717	CcSEcCtD
Irbesartan—Connective tissue disorder—Riluzole—amyotrophic lateral sclerosis	0.00238	0.00715	CcSEcCtD
Irbesartan—Urethral disorder—Riluzole—amyotrophic lateral sclerosis	0.00237	0.00713	CcSEcCtD
Irbesartan—JUN—spinal cord—amyotrophic lateral sclerosis	0.00232	0.0353	CbGeAlD
Irbesartan—Cardiac disorder—Riluzole—amyotrophic lateral sclerosis	0.00225	0.00675	CcSEcCtD
Irbesartan—Angiopathy—Riluzole—amyotrophic lateral sclerosis	0.0022	0.0066	CcSEcCtD
Irbesartan—Immune system disorder—Riluzole—amyotrophic lateral sclerosis	0.00219	0.00657	CcSEcCtD
Irbesartan—Mediastinal disorder—Riluzole—amyotrophic lateral sclerosis	0.00218	0.00656	CcSEcCtD
Irbesartan—Chills—Riluzole—amyotrophic lateral sclerosis	0.00217	0.00653	CcSEcCtD
Irbesartan—Arrhythmia—Riluzole—amyotrophic lateral sclerosis	0.00216	0.0065	CcSEcCtD
Irbesartan—Malnutrition—Riluzole—amyotrophic lateral sclerosis	0.00211	0.00633	CcSEcCtD
Irbesartan—Flatulence—Riluzole—amyotrophic lateral sclerosis	0.00208	0.00624	CcSEcCtD
Irbesartan—Tension—Riluzole—amyotrophic lateral sclerosis	0.00207	0.00622	CcSEcCtD
Irbesartan—Dysgeusia—Riluzole—amyotrophic lateral sclerosis	0.00206	0.0062	CcSEcCtD
Irbesartan—Nervousness—Riluzole—amyotrophic lateral sclerosis	0.00205	0.00615	CcSEcCtD
Irbesartan—Muscle spasms—Riluzole—amyotrophic lateral sclerosis	0.00203	0.00609	CcSEcCtD
Irbesartan—Tremor—Riluzole—amyotrophic lateral sclerosis	0.00197	0.00593	CcSEcCtD
Irbesartan—AGTR1—medulla oblongata—amyotrophic lateral sclerosis	0.00196	0.0298	CbGeAlD
Irbesartan—JUN—nervous system—amyotrophic lateral sclerosis	0.00196	0.0298	CbGeAlD
Irbesartan—Ill-defined disorder—Riluzole—amyotrophic lateral sclerosis	0.00196	0.00588	CcSEcCtD
Irbesartan—Anaemia—Riluzole—amyotrophic lateral sclerosis	0.00195	0.00585	CcSEcCtD
Irbesartan—Agitation—Riluzole—amyotrophic lateral sclerosis	0.00194	0.00582	CcSEcCtD
Irbesartan—Angioedema—Riluzole—amyotrophic lateral sclerosis	0.00193	0.00579	CcSEcCtD
Irbesartan—Malaise—Riluzole—amyotrophic lateral sclerosis	0.0019	0.00571	CcSEcCtD
Irbesartan—Vertigo—Riluzole—amyotrophic lateral sclerosis	0.00189	0.00569	CcSEcCtD
Irbesartan—Syncope—Riluzole—amyotrophic lateral sclerosis	0.00189	0.00568	CcSEcCtD
Irbesartan—Leukopenia—Riluzole—amyotrophic lateral sclerosis	0.00189	0.00567	CcSEcCtD
Irbesartan—JUN—central nervous system—amyotrophic lateral sclerosis	0.00188	0.0287	CbGeAlD
Irbesartan—Loss of consciousness—Riluzole—amyotrophic lateral sclerosis	0.00185	0.00557	CcSEcCtD
Irbesartan—JUN—cerebellum—amyotrophic lateral sclerosis	0.00184	0.028	CbGeAlD
Irbesartan—Cough—Riluzole—amyotrophic lateral sclerosis	0.00184	0.00553	CcSEcCtD
Irbesartan—Hypertension—Riluzole—amyotrophic lateral sclerosis	0.00182	0.00547	CcSEcCtD
Irbesartan—Myalgia—Riluzole—amyotrophic lateral sclerosis	0.00179	0.00539	CcSEcCtD
Irbesartan—Arthralgia—Riluzole—amyotrophic lateral sclerosis	0.00179	0.00539	CcSEcCtD
Irbesartan—Chest pain—Riluzole—amyotrophic lateral sclerosis	0.00179	0.00539	CcSEcCtD
Irbesartan—Anxiety—Riluzole—amyotrophic lateral sclerosis	0.00179	0.00537	CcSEcCtD
Irbesartan—Unspecified disorder of skin and subcutaneous tissue—Riluzole—amyotrophic lateral sclerosis	0.00178	0.00536	CcSEcCtD
Irbesartan—Discomfort—Riluzole—amyotrophic lateral sclerosis	0.00177	0.00533	CcSEcCtD
Irbesartan—CYP2D6—hindbrain—amyotrophic lateral sclerosis	0.00177	0.027	CbGeAlD
Irbesartan—Dry mouth—Riluzole—amyotrophic lateral sclerosis	0.00176	0.00527	CcSEcCtD
Irbesartan—Anaphylactic shock—Riluzole—amyotrophic lateral sclerosis	0.00172	0.00517	CcSEcCtD
Irbesartan—Oedema—Riluzole—amyotrophic lateral sclerosis	0.00172	0.00517	CcSEcCtD
Irbesartan—Infection—Riluzole—amyotrophic lateral sclerosis	0.00171	0.00514	CcSEcCtD
Irbesartan—Shock—Riluzole—amyotrophic lateral sclerosis	0.00169	0.00509	CcSEcCtD
Irbesartan—Nervous system disorder—Riluzole—amyotrophic lateral sclerosis	0.00169	0.00507	CcSEcCtD
Irbesartan—Thrombocytopenia—Riluzole—amyotrophic lateral sclerosis	0.00168	0.00506	CcSEcCtD
Irbesartan—Tachycardia—Riluzole—amyotrophic lateral sclerosis	0.00168	0.00505	CcSEcCtD
Irbesartan—Skin disorder—Riluzole—amyotrophic lateral sclerosis	0.00167	0.00502	CcSEcCtD
Irbesartan—Hyperhidrosis—Riluzole—amyotrophic lateral sclerosis	0.00166	0.005	CcSEcCtD
Irbesartan—Anorexia—Riluzole—amyotrophic lateral sclerosis	0.00164	0.00493	CcSEcCtD
Irbesartan—EDNRA—brain—amyotrophic lateral sclerosis	0.00164	0.0249	CbGeAlD
Irbesartan—Hypotension—Riluzole—amyotrophic lateral sclerosis	0.00161	0.00483	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Riluzole—amyotrophic lateral sclerosis	0.00157	0.00471	CcSEcCtD
Irbesartan—Paraesthesia—Riluzole—amyotrophic lateral sclerosis	0.00154	0.00464	CcSEcCtD
Irbesartan—Dyspnoea—Riluzole—amyotrophic lateral sclerosis	0.00153	0.00461	CcSEcCtD
Irbesartan—Somnolence—Riluzole—amyotrophic lateral sclerosis	0.00153	0.0046	CcSEcCtD
Irbesartan—Dyspepsia—Riluzole—amyotrophic lateral sclerosis	0.00151	0.00455	CcSEcCtD
Irbesartan—Decreased appetite—Riluzole—amyotrophic lateral sclerosis	0.0015	0.00449	CcSEcCtD
Irbesartan—JUN—brain—amyotrophic lateral sclerosis	0.0015	0.0228	CbGeAlD
Irbesartan—Gastrointestinal disorder—Riluzole—amyotrophic lateral sclerosis	0.00149	0.00446	CcSEcCtD
Irbesartan—Fatigue—Riluzole—amyotrophic lateral sclerosis	0.00148	0.00446	CcSEcCtD
Irbesartan—AGTR1—nervous system—amyotrophic lateral sclerosis	0.00147	0.0224	CbGeAlD
Irbesartan—Constipation—Riluzole—amyotrophic lateral sclerosis	0.00147	0.00442	CcSEcCtD
Irbesartan—Pain—Riluzole—amyotrophic lateral sclerosis	0.00147	0.00442	CcSEcCtD
Irbesartan—AGTR1—central nervous system—amyotrophic lateral sclerosis	0.00142	0.0216	CbGeAlD
Irbesartan—Feeling abnormal—Riluzole—amyotrophic lateral sclerosis	0.00142	0.00426	CcSEcCtD
Irbesartan—Gastrointestinal pain—Riluzole—amyotrophic lateral sclerosis	0.00141	0.00423	CcSEcCtD
Irbesartan—Urticaria—Riluzole—amyotrophic lateral sclerosis	0.00137	0.00411	CcSEcCtD
Irbesartan—Abdominal pain—Riluzole—amyotrophic lateral sclerosis	0.00136	0.00409	CcSEcCtD
Irbesartan—Body temperature increased—Riluzole—amyotrophic lateral sclerosis	0.00136	0.00409	CcSEcCtD
Irbesartan—Hypersensitivity—Riluzole—amyotrophic lateral sclerosis	0.00127	0.00381	CcSEcCtD
Irbesartan—Asthenia—Riluzole—amyotrophic lateral sclerosis	0.00123	0.00371	CcSEcCtD
Irbesartan—Pruritus—Riluzole—amyotrophic lateral sclerosis	0.00122	0.00366	CcSEcCtD
Irbesartan—Diarrhoea—Riluzole—amyotrophic lateral sclerosis	0.00118	0.00354	CcSEcCtD
Irbesartan—Dizziness—Riluzole—amyotrophic lateral sclerosis	0.00114	0.00342	CcSEcCtD
Irbesartan—AGTR1—brain—amyotrophic lateral sclerosis	0.00113	0.0171	CbGeAlD
Irbesartan—Vomiting—Riluzole—amyotrophic lateral sclerosis	0.00109	0.00329	CcSEcCtD
Irbesartan—Rash—Riluzole—amyotrophic lateral sclerosis	0.00108	0.00326	CcSEcCtD
Irbesartan—Dermatitis—Riluzole—amyotrophic lateral sclerosis	0.00108	0.00326	CcSEcCtD
Irbesartan—Headache—Riluzole—amyotrophic lateral sclerosis	0.00108	0.00324	CcSEcCtD
Irbesartan—Nausea—Riluzole—amyotrophic lateral sclerosis	0.00102	0.00307	CcSEcCtD
Irbesartan—CYP2D6—brainstem—amyotrophic lateral sclerosis	0.00102	0.0155	CbGeAlD
Irbesartan—PTGS1—spinal cord—amyotrophic lateral sclerosis	0.000769	0.0117	CbGeAlD
Irbesartan—PTGS1—nervous system—amyotrophic lateral sclerosis	0.000648	0.00986	CbGeAlD
Irbesartan—PTGS1—central nervous system—amyotrophic lateral sclerosis	0.000623	0.00949	CbGeAlD
Irbesartan—CYP2C8—brain—amyotrophic lateral sclerosis	0.00061	0.00929	CbGeAlD
Irbesartan—CYP3A4—nervous system—amyotrophic lateral sclerosis	0.000541	0.00823	CbGeAlD
Irbesartan—CYP2D6—nervous system—amyotrophic lateral sclerosis	0.000532	0.0081	CbGeAlD
Irbesartan—CYP3A4—central nervous system—amyotrophic lateral sclerosis	0.000521	0.00793	CbGeAlD
Irbesartan—CYP2D6—central nervous system—amyotrophic lateral sclerosis	0.000512	0.0078	CbGeAlD
Irbesartan—CYP2D6—cerebellum—amyotrophic lateral sclerosis	0.000501	0.00762	CbGeAlD
Irbesartan—PTGS1—brain—amyotrophic lateral sclerosis	0.000495	0.00753	CbGeAlD
Irbesartan—CYP2D6—brain—amyotrophic lateral sclerosis	0.000407	0.00619	CbGeAlD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—VAPB—amyotrophic lateral sclerosis	0.000274	0.00162	CbGpPWpGaD
Irbesartan—CYP1A2—Arachidonic acid metabolism—PLA2G4A—amyotrophic lateral sclerosis	0.000273	0.00161	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	0.000271	0.0016	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—FIG4—amyotrophic lateral sclerosis	0.000268	0.00158	CbGpPWpGaD
Irbesartan—JUN—Immune System—KIFAP3—amyotrophic lateral sclerosis	0.000265	0.00157	CbGpPWpGaD
Irbesartan—JUN—Cellular responses to stress—SOD1—amyotrophic lateral sclerosis	0.000256	0.00152	CbGpPWpGaD
Irbesartan—JUN—Cellular responses to stress—GSTP1—amyotrophic lateral sclerosis	0.00025	0.00148	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	0.00025	0.00148	CbGpPWpGaD
Irbesartan—CYP1A2—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	0.000247	0.00146	CbGpPWpGaD
Irbesartan—PTGS1—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	0.000246	0.00146	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—DAO—amyotrophic lateral sclerosis	0.000242	0.00143	CbGpPWpGaD
Irbesartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—C3—amyotrophic lateral sclerosis	0.000237	0.0014	CbGpPWpGaD
Irbesartan—AGTR1—GPCR downstream signaling—C5AR1—amyotrophic lateral sclerosis	0.000234	0.00138	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	0.000233	0.00138	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	0.000232	0.00137	CbGpPWpGaD
Irbesartan—EDNRA—GPCR ligand binding—C3—amyotrophic lateral sclerosis	0.00023	0.00136	CbGpPWpGaD
Irbesartan—JUN—AP-1 transcription factor network—TP53—amyotrophic lateral sclerosis	0.000223	0.00132	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—VAPB—amyotrophic lateral sclerosis	0.000223	0.00132	CbGpPWpGaD
Irbesartan—CYP2C8—Arachidonic acid metabolism—PTGS2—amyotrophic lateral sclerosis	0.000221	0.00131	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	0.000219	0.00129	CbGpPWpGaD
Irbesartan—PTGS1—Selenium Micronutrient Network—PTGS2—amyotrophic lateral sclerosis	0.000218	0.00129	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	0.000213	0.00126	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	0.000211	0.00125	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	0.000204	0.0012	CbGpPWpGaD
Irbesartan—JUN—Focal Adhesion—IGF1—amyotrophic lateral sclerosis	0.000203	0.0012	CbGpPWpGaD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—IGF1—amyotrophic lateral sclerosis	0.000203	0.0012	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	0.000199	0.00117	CbGpPWpGaD
Irbesartan—JUN—Glucocorticoid receptor regulatory network—TP53—amyotrophic lateral sclerosis	0.000197	0.00116	CbGpPWpGaD
Irbesartan—JUN—BDNF signaling pathway—CASP3—amyotrophic lateral sclerosis	0.000196	0.00116	CbGpPWpGaD
Irbesartan—JUN—Apoptosis—TP53—amyotrophic lateral sclerosis	0.000193	0.00114	CbGpPWpGaD
Irbesartan—CYP3A4—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	0.000191	0.00113	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—VAPB—amyotrophic lateral sclerosis	0.00019	0.00113	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	0.000189	0.00112	CbGpPWpGaD
Irbesartan—CYP1A2—Phase II conjugation—GSTP1—amyotrophic lateral sclerosis	0.000189	0.00112	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—VAPB—amyotrophic lateral sclerosis	0.000189	0.00112	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—TPK1—amyotrophic lateral sclerosis	0.000189	0.00112	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—VCP—amyotrophic lateral sclerosis	0.000188	0.00111	CbGpPWpGaD
Irbesartan—JUN—Integrated Breast Cancer Pathway—CASP3—amyotrophic lateral sclerosis	0.000188	0.00111	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—PLB1—amyotrophic lateral sclerosis	0.000184	0.00109	CbGpPWpGaD
Irbesartan—JUN—SIDS Susceptibility Pathways—CASP3—amyotrophic lateral sclerosis	0.000183	0.00108	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	0.000182	0.00108	CbGpPWpGaD
Irbesartan—JUN—Apoptosis Modulation and Signaling—TP53—amyotrophic lateral sclerosis	0.000181	0.00107	CbGpPWpGaD
Irbesartan—AGTR1—GPCR ligand binding—C3—amyotrophic lateral sclerosis	0.000181	0.00107	CbGpPWpGaD
Irbesartan—CYP2C9—Arachidonic acid metabolism—PTGS2—amyotrophic lateral sclerosis	0.00018	0.00107	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	0.000178	0.00105	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	0.000176	0.00104	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	0.000174	0.00103	CbGpPWpGaD
Irbesartan—JUN—MAPK Signaling Pathway—CASP3—amyotrophic lateral sclerosis	0.000173	0.00102	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—VAPA—amyotrophic lateral sclerosis	0.000173	0.00102	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—GSR—amyotrophic lateral sclerosis	0.000169	0.001	CbGpPWpGaD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—PTGS2—amyotrophic lateral sclerosis	0.000168	0.000993	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	0.000166	0.00098	CbGpPWpGaD
Irbesartan—JUN—Wnt Signaling Pathway and Pluripotency—TP53—amyotrophic lateral sclerosis	0.000165	0.000977	CbGpPWpGaD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—amyotrophic lateral sclerosis	0.000165	0.000973	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	0.000162	0.000957	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	0.000162	0.000957	CbGpPWpGaD
Irbesartan—JUN—Senescence and Autophagy in Cancer—TP53—amyotrophic lateral sclerosis	0.000161	0.000954	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—ATF1—amyotrophic lateral sclerosis	0.000161	0.000949	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.00016	0.000948	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	0.00016	0.000946	CbGpPWpGaD
Irbesartan—JUN—Integrated Breast Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	0.00016	0.000944	CbGpPWpGaD
Irbesartan—CYP2C8—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	0.000159	0.00094	CbGpPWpGaD
Irbesartan—CYP2C8—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	0.000157	0.000927	CbGpPWpGaD
Irbesartan—JUN—Signaling by NOTCH—TP53—amyotrophic lateral sclerosis	0.000157	0.000926	CbGpPWpGaD
Irbesartan—JUN—DNA Damage Response (only ATM dependent)—TP53—amyotrophic lateral sclerosis	0.000157	0.000926	CbGpPWpGaD
Irbesartan—JUN—Immune System—DCTN1—amyotrophic lateral sclerosis	0.000156	0.000923	CbGpPWpGaD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—CASP3—amyotrophic lateral sclerosis	0.000156	0.000922	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	0.000156	0.000921	CbGpPWpGaD
Irbesartan—JUN—SIDS Susceptibility Pathways—VEGFA—amyotrophic lateral sclerosis	0.000156	0.00092	CbGpPWpGaD
Irbesartan—CYP1A2—Arachidonic acid metabolism—PTGS2—amyotrophic lateral sclerosis	0.000154	0.00091	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—CASP9—amyotrophic lateral sclerosis	0.000153	0.000904	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	0.000152	0.000899	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—FIG4—amyotrophic lateral sclerosis	0.000151	0.000892	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	0.00015	0.000886	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—VCP—amyotrophic lateral sclerosis	0.000148	0.000873	CbGpPWpGaD
Irbesartan—JUN—Oxidative Stress Induced Senescence—TP53—amyotrophic lateral sclerosis	0.000146	0.000863	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	0.000143	0.000846	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—CHAT—amyotrophic lateral sclerosis	0.000139	0.000822	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—DAO—amyotrophic lateral sclerosis	0.000136	0.000806	CbGpPWpGaD
Irbesartan—JUN—TGF-beta Signaling Pathway—TP53—amyotrophic lateral sclerosis	0.000134	0.000795	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	0.000134	0.000791	CbGpPWpGaD
Irbesartan—JUN—Focal Adhesion—VEGFA—amyotrophic lateral sclerosis	0.000133	0.000786	CbGpPWpGaD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	0.000132	0.000783	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—ERBB4—amyotrophic lateral sclerosis	0.000131	0.000774	CbGpPWpGaD
Irbesartan—CYP2D6—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	0.000131	0.000772	CbGpPWpGaD
Irbesartan—EDNRA—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	0.00013	0.00077	CbGpPWpGaD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—amyotrophic lateral sclerosis	0.00013	0.000766	CbGpPWpGaD
Irbesartan—CYP2C9—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	0.000129	0.000765	CbGpPWpGaD
Irbesartan—CYP2D6—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	0.000129	0.000761	CbGpPWpGaD
Irbesartan—JUN—Direct p53 effectors—TP53—amyotrophic lateral sclerosis	0.000128	0.000758	CbGpPWpGaD
Irbesartan—CYP2C9—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	0.000128	0.000755	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	0.000127	0.000751	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	0.000126	0.000743	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	0.000124	0.000732	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	0.000122	0.000721	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—VAPB—amyotrophic lateral sclerosis	0.000122	0.00072	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—TPK1—amyotrophic lateral sclerosis	0.000122	0.00072	CbGpPWpGaD
Irbesartan—JUN—Integrated Breast Cancer Pathway—TP53—amyotrophic lateral sclerosis	0.000121	0.000714	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—C3—amyotrophic lateral sclerosis	0.000118	0.000699	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	0.000116	0.000688	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	0.000114	0.000672	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—VAPA—amyotrophic lateral sclerosis	0.000111	0.000659	CbGpPWpGaD
Irbesartan—JUN—MAPK Signaling Pathway—TP53—amyotrophic lateral sclerosis	0.000111	0.000655	CbGpPWpGaD
Irbesartan—CYP1A2—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	0.000111	0.000654	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—VCP—amyotrophic lateral sclerosis	0.00011	0.000652	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	0.00011	0.00065	CbGpPWpGaD
Irbesartan—CYP1A2—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	0.000109	0.000645	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—C3—amyotrophic lateral sclerosis	0.000109	0.000643	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	0.000107	0.000632	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	0.000105	0.000621	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	0.000104	0.000616	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.000104	0.000613	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—PLB1—amyotrophic lateral sclerosis	0.000103	0.000611	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	0.000103	0.00061	CbGpPWpGaD
Irbesartan—AGTR1—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	0.000102	0.000604	CbGpPWpGaD
Irbesartan—JUN—Cellular responses to stress—VEGFA—amyotrophic lateral sclerosis	0.000102	0.000604	CbGpPWpGaD
Irbesartan—JUN—Cellular Senescence—TP53—amyotrophic lateral sclerosis	0.000102	0.000604	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—VAPB—amyotrophic lateral sclerosis	0.0001	0.000591	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—TPK1—amyotrophic lateral sclerosis	0.0001	0.000591	CbGpPWpGaD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—TP53—amyotrophic lateral sclerosis	0.0001	0.000591	CbGpPWpGaD
Irbesartan—JUN—Immune System—SQSTM1—amyotrophic lateral sclerosis	9.97e-05	0.00059	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—TPK1—amyotrophic lateral sclerosis	9.92e-05	0.000586	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—VAPB—amyotrophic lateral sclerosis	9.92e-05	0.000586	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	9.82e-05	0.000581	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—FIG4—amyotrophic lateral sclerosis	9.74e-05	0.000576	CbGpPWpGaD
Irbesartan—JUN—Circadian rythm related genes—TP53—amyotrophic lateral sclerosis	9.6e-05	0.000568	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—GSR—amyotrophic lateral sclerosis	9.54e-05	0.000564	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	9.49e-05	0.000561	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	9.38e-05	0.000555	CbGpPWpGaD
Irbesartan—JUN—Immune System—ATF1—amyotrophic lateral sclerosis	9.35e-05	0.000553	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—C3—amyotrophic lateral sclerosis	9.28e-05	0.000549	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	9.25e-05	0.000547	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—VAPA—amyotrophic lateral sclerosis	9.15e-05	0.000541	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—VAPA—amyotrophic lateral sclerosis	9.07e-05	0.000536	CbGpPWpGaD
Irbesartan—JUN—Immune System—CASP9—amyotrophic lateral sclerosis	8.91e-05	0.000527	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—DAO—amyotrophic lateral sclerosis	8.81e-05	0.000521	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	8.69e-05	0.000514	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	8.63e-05	0.00051	CbGpPWpGaD
Irbesartan—CYP3A4—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	8.54e-05	0.000505	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—SACM1L—amyotrophic lateral sclerosis	8.51e-05	0.000503	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—VAPB—amyotrophic lateral sclerosis	8.48e-05	0.000501	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—TPK1—amyotrophic lateral sclerosis	8.48e-05	0.000501	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—SACM1L—amyotrophic lateral sclerosis	8.43e-05	0.000499	CbGpPWpGaD
Irbesartan—CYP3A4—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	8.42e-05	0.000498	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	8.41e-05	0.000497	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	8.09e-05	0.000479	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—FIG4—amyotrophic lateral sclerosis	8e-05	0.000473	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—FIG4—amyotrophic lateral sclerosis	7.93e-05	0.000469	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	7.91e-05	0.000467	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	7.9e-05	0.000467	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—CHAT—amyotrophic lateral sclerosis	7.83e-05	0.000463	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—VAPA—amyotrophic lateral sclerosis	7.75e-05	0.000458	CbGpPWpGaD
Irbesartan—JUN—Cellular responses to stress—TP53—amyotrophic lateral sclerosis	7.72e-05	0.000456	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	7.71e-05	0.000456	CbGpPWpGaD
Irbesartan—JUN—Immune System—ERBB4—amyotrophic lateral sclerosis	7.62e-05	0.000451	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—GSTP1—amyotrophic lateral sclerosis	7.48e-05	0.000442	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—DAO—amyotrophic lateral sclerosis	7.23e-05	0.000428	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—SACM1L—amyotrophic lateral sclerosis	7.21e-05	0.000426	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—DAO—amyotrophic lateral sclerosis	7.17e-05	0.000424	CbGpPWpGaD
Irbesartan—JUN—Immune System—CD40LG—amyotrophic lateral sclerosis	7.17e-05	0.000424	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	7.15e-05	0.000423	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—C3—amyotrophic lateral sclerosis	6.99e-05	0.000413	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	6.87e-05	0.000406	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—FIG4—amyotrophic lateral sclerosis	6.78e-05	0.000401	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PLB1—amyotrophic lateral sclerosis	6.68e-05	0.000395	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	6.6e-05	0.00039	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—TPK1—amyotrophic lateral sclerosis	6.54e-05	0.000387	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—VAPB—amyotrophic lateral sclerosis	6.54e-05	0.000387	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—APOE—amyotrophic lateral sclerosis	6.5e-05	0.000385	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	6.45e-05	0.000381	CbGpPWpGaD
Irbesartan—JUN—Immune System—C3—amyotrophic lateral sclerosis	6.34e-05	0.000375	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	6.2e-05	0.000367	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—GSR—amyotrophic lateral sclerosis	6.16e-05	0.000364	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—DAO—amyotrophic lateral sclerosis	6.13e-05	0.000362	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	6.05e-05	0.000358	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—VAPA—amyotrophic lateral sclerosis	5.98e-05	0.000354	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	5.76e-05	0.00034	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—APOE—amyotrophic lateral sclerosis	5.65e-05	0.000334	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	5.61e-05	0.000332	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—SACM1L—amyotrophic lateral sclerosis	5.56e-05	0.000329	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—C3—amyotrophic lateral sclerosis	5.48e-05	0.000324	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PLB1—amyotrophic lateral sclerosis	5.48e-05	0.000324	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PLB1—amyotrophic lateral sclerosis	5.43e-05	0.000321	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	5.37e-05	0.000318	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—FIG4—amyotrophic lateral sclerosis	5.23e-05	0.000309	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—APOE—amyotrophic lateral sclerosis	5.1e-05	0.000302	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—CHAT—amyotrophic lateral sclerosis	5.06e-05	0.000299	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—GSR—amyotrophic lateral sclerosis	5.06e-05	0.000299	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—GSR—amyotrophic lateral sclerosis	5.02e-05	0.000297	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	4.93e-05	0.000291	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	4.9e-05	0.00029	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—DAO—amyotrophic lateral sclerosis	4.73e-05	0.00028	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PLB1—amyotrophic lateral sclerosis	4.64e-05	0.000275	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	4.63e-05	0.000274	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	4.62e-05	0.000273	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	4.57e-05	0.00027	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—GSR—amyotrophic lateral sclerosis	4.29e-05	0.000253	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	4.22e-05	0.000249	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—GSTP1—amyotrophic lateral sclerosis	4.21e-05	0.000249	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—CHAT—amyotrophic lateral sclerosis	4.15e-05	0.000246	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	4.14e-05	0.000245	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—CHAT—amyotrophic lateral sclerosis	4.12e-05	0.000243	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—C3—amyotrophic lateral sclerosis	4.1e-05	0.000242	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	3.91e-05	0.000231	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	3.9e-05	0.000231	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—PTGS2—amyotrophic lateral sclerosis	3.87e-05	0.000229	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	3.87e-05	0.000229	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—APOE—amyotrophic lateral sclerosis	3.81e-05	0.000225	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	3.76e-05	0.000222	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PLB1—amyotrophic lateral sclerosis	3.58e-05	0.000212	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—CHAT—amyotrophic lateral sclerosis	3.52e-05	0.000208	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	3.51e-05	0.000208	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—GSR—amyotrophic lateral sclerosis	3.31e-05	0.000196	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	3.25e-05	0.000192	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	3.21e-05	0.00019	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—APOE—amyotrophic lateral sclerosis	3.18e-05	0.000188	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	3.16e-05	0.000187	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	3.15e-05	0.000186	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	3.07e-05	0.000181	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	2.75e-05	0.000163	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—GSTP1—amyotrophic lateral sclerosis	2.72e-05	0.000161	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—CHAT—amyotrophic lateral sclerosis	2.72e-05	0.000161	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—TP53—amyotrophic lateral sclerosis	2.65e-05	0.000157	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	2.57e-05	0.000152	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	2.5e-05	0.000148	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	2.43e-05	0.000143	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	2.29e-05	0.000136	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—GSTP1—amyotrophic lateral sclerosis	2.23e-05	0.000132	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—GSTP1—amyotrophic lateral sclerosis	2.21e-05	0.000131	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	2.2e-05	0.00013	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—PTGS2—amyotrophic lateral sclerosis	2.18e-05	0.000129	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—TP53—amyotrophic lateral sclerosis	2.08e-05	0.000123	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	2.06e-05	0.000122	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—APOE—amyotrophic lateral sclerosis	2.06e-05	0.000122	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	2.05e-05	0.000121	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	2.03e-05	0.00012	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.89e-05	0.000112	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.74e-05	0.000103	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—APOE—amyotrophic lateral sclerosis	1.69e-05	9.98e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—APOE—amyotrophic lateral sclerosis	1.67e-05	9.89e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—TP53—amyotrophic lateral sclerosis	1.56e-05	9.19e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.46e-05	8.63e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—APOE—amyotrophic lateral sclerosis	1.43e-05	8.46e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.41e-05	8.33e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.34e-05	7.93e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.16e-05	6.84e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.15e-05	6.78e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—APOE—amyotrophic lateral sclerosis	1.1e-05	6.53e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PTGS2—amyotrophic lateral sclerosis	9.8e-06	5.79e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PTGS2—amyotrophic lateral sclerosis	7.56e-06	4.47e-05	CbGpPWpGaD
